SJS Investment Consulting’s Celldex Therapeutics CLDX Stock Holding History

SJS Investment Consulting’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.9K	Buy	+51	New	+$1.65K	﹤0.01%	1796

Other funds holding CLDX

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

MCP

Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return

Apella Capital West Hartford, Connecticut $7.08B AUM 17.38% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

SJS Investment Consulting's CLDX Position: Q2 2026 in Review

SJS Investment Consulting opened a new position in Celldex Therapeutics (CLDX) in Q2 2026: 51 shares worth $1.9K. The stake represents ﹤0.01% of the portfolio and ranks #1796 among its holdings.

41 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

SJS Investment Consulting held 51 shares of Celldex Therapeutics worth $1.9K as of Q2 2026.
Celldex Therapeutics was a new SJS Investment Consulting position in Q2 2026.
Celldex Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1796 holding.
41 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.